NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
NITROGEN, NF (nitrogen) by Advanced Solutions Life Sciences. Approved for critical illness, nutrition therapy, postoperative complications and 2 more indications. First approved in 2013.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITROGEN, NF is an inhaled gas therapeutic approved in 2013 for use in critical illness, nutrition therapy, postoperative complications, superficial basal cell carcinoma, and gastrointestinal neoplasms. The product is a non-pharmaceutical nitrogen gas formulation with no defined mechanism of action in the clinical data. It represents a niche therapeutic gas modality with multiple clinical applications across oncology and critical care settings.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting stable but non-growth commercial operations and smaller brand team support needs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on NITROGEN, NF at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.